Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
GeriPal
DECEMBER 15, 2022
In an article in the NEJM (a published article this time, wonder of wonders!) We’ve talked at length on prior podcasts about the failures of aducnumab, Biogen, and the FDA’s decision to approve it. . But wait, there’s a shiny new anti-amyloid drug, lecanemab! (No No it’s not just the French version of Aducanumab). . Transcript.
Let's personalize your content